JRGD:XETRA:XETRA-JPMorgan ETFs (Ireland) ICAV - Global Research Enhanced Index Equity UCITS ETF - USD (dist) (EUR)

ETF | Others |

Last Closing

USD 41.405

Change

-0.06 (-0.14)%

Market Cap

USD 2.00M

Volume

1.90K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.60 (+1.20%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.19 (+1.23%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.24 (+0.94%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.31 (+1.15%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.27 (+1.14%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.52 (-0.34%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+2.54 (+1.86%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.38 (+0.89%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.60 (+1.21%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+10.20 (+2.07%)

USD 80.38B

ETFs Containing JRGD:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.80% 82% B 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.80% 82% B 80% B-
Trailing 12 Months  
Capital Gain 27.79% 81% B- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.79% 81% B- 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.36% 54% F 53% F
Dividend Return 4.36% 54% F 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.63% 70% C- 76% C+
Risk Adjusted Return 57.13% 80% B- 80% B-
Market Capitalization 2.00M 2% F 2% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.